Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Contact Us

To learn more about Avalanche and our therapies for treating eye-related diseases, contact us.

Avalanche Biotechnologies
1035 O’Brien Drive, Suite A
Menlo Park, CA 94025

Tel: 650-272-6269
Fax: 650-362-1908

Email:

General Inquiry: info@avalanchebiotech.com
Careers: careers@avalanchebiotech.com
Business Development: busdev@avalanchebiotech.com


Or Submit This Contact Form:

Send To:
First Name:*
Last Name:*
Title:
Company Name:*
E-mail Address:*
Phone Number:
Message:*
 

Avalanche Biotechnologies, Inc. Announces Positive Top-Line Phase 2a Results for AVA-101 in Wet Age-Related Macular Degeneration

June 15, 2015

MENLO PARK, Calif., June 15, 2015 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL) today announced that its Phase 2a clinical study for AVA-101 met its 12-month primary endpoint, based on ophthalmic and systemic safety, demonstrating that AVA-101 was well tolerated with a favorable safety profile in subjects with wet age-related macular degeneration (wet AMD).

Read More

Read All Avalanche News